Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Link Between Non-Alcoholic Fatty Liver Disease and Certain Cancers

      December 27, 2017
      By Lisa Schulmeister, MN, RN, ACNS-BC, FAAN
      Article

      Non-alcoholic fatty liver disease (NAFLD) is a risk factor for cancer, according to a recent report about a 7.5-year Korean study.

      People with non-alcoholic fatty liver disease (NAFLD) are at a greater risk of developing cancer that those who don't have it, according to a study published in the Journal of Hepatology.

      Researchers in Korea investigated Korean cancer incidence rates among people with NAFLD since there has been insufficient data on whether there is an association between the two. Ultrasonography was used to diagnose NAFLD in the absence of known liver disease, including alcohol-related and viral hepatitis.

      Of 25,947 people studied, 8721 (33.6%) had NAFLD. During the follow-up that averaged 7.5 years, the cancer incidence rate of the NAFLD group was significantly higher than that of the non-NAFLD group. NAFLD was associated with the development of 3 cancers: hepatocellular carcinoma, colorectal cancer in men, and breast cancer in women. Although the study followed Korean patients, the large number of people studied suggests that NAFLD may be prevalent in other countries, too.

      Since NAFLD is affected by the amount of fat in the liver, people who are overweight or obese, have diabetes, or high blood pressure often are at risk. The number of these people worldwide is growing; consequently, the incidence of NAFLD may rise. The American Liver Foundation cites a 25% incidence of NAFLD among Americans, so clinicians in the United States need to be aware of the association between NAFLD and cancer, and screen people at high risk.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a man wearing a suit with a bowtie in front of an Oncology Nursing News backdrop
      Image of a nurse handing a patient pills
      Photo of an open bottle of pills
      Related Content

      Photo of a syringe and a vaccine bottle

      Amphiphile Vaccine Extends RFS in KRAS+ Pancreatic Cancer

      Jonah Feldman
      September 12th 2025
      Article

      The Vitals

      ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

      Lindsay Fischer
      September 12th 2025
      Podcast

      Graphic of a person's gastrointestinal tract.

      Retifanlimab Lengthens Survival for Patients With Anal Cancer

      Sabrina Serani
      September 12th 2025
      Article

      The Vitals

      Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium

      Lindsay Fischer
      September 12th 2025
      Podcast

      Graphic of a person's esophagus and stomach

      Zanidatamab/Chemo Yields Durable Response in HER2+ Gastroesophageal Cancer

      Russ Conroy
      September 12th 2025
      Article

      Anatomical image of a pancreas with tumors

      Atebimetinib Combo Shows Survival Signal in First-Line Pancreatic Cancer

      Chris Ryan
      September 12th 2025
      Article
      Related Content

      Photo of a syringe and a vaccine bottle

      Amphiphile Vaccine Extends RFS in KRAS+ Pancreatic Cancer

      Jonah Feldman
      September 12th 2025
      Article

      The Vitals

      ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

      Lindsay Fischer
      September 12th 2025
      Podcast

      Graphic of a person's gastrointestinal tract.

      Retifanlimab Lengthens Survival for Patients With Anal Cancer

      Sabrina Serani
      September 12th 2025
      Article

      The Vitals

      Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium

      Lindsay Fischer
      September 12th 2025
      Podcast

      Graphic of a person's esophagus and stomach

      Zanidatamab/Chemo Yields Durable Response in HER2+ Gastroesophageal Cancer

      Russ Conroy
      September 12th 2025
      Article

      Anatomical image of a pancreas with tumors

      Atebimetinib Combo Shows Survival Signal in First-Line Pancreatic Cancer

      Chris Ryan
      September 12th 2025
      Article

      Latest Conference Coverage

      Safety Management With Amivantamab Plus Lazertinib in NSCLC

      Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC

      Adverse Events of Menin Inhibitors in AML: What Nurses Should Know

      Ivonescimab/Chemo Ups PFS After Third-Generation TKI in EGFR+ NSCLC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      259 Prospect Plains Rd, Bldg H,
      Monroe, NJ 08831

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.